Finanzen von Galectin Therapeutics Inc (GALT)GALTGalectin Therapeutics Inc

In the context of the broader market, GALT competes directly with industry leaders such as LXEO and LRMR. With a market capitalization of $420.54M, it holds a leading position in the sector. When comparing efficiency, GALT's gross margin of N/A stands against LXEO's N/A and LRMR's N/A. Such benchmarking helps identify whether Galectin Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Galectin Therapeutics has shown a significant increase in its stock price over the last month, with a 20-day change of +35.35%. However, the company reported a net loss of $9.11 million in Q2, which is a 21% increase from the previous year, indicating financial strain.